Author’s response to reviews

Title: Targeting Molecular Resistance in Castration-Resistant Prostate Cancer

Authors:

Thenappan Chandrasekar (tchandrasekar@ucdavis.edu)
Joy C Yang (jcyang@ucdavis.edu)
Allen C Gao (acgao@ucdavis.edu)
Christopher P Evans (cpevans@ucdavis.edu)

Version: 5 Date: 17 August 2015

Author’s response to reviews: see over
Dr. Alam:

Please find below a complete response to the third round of reviews submitted for our manuscript, as well as answers to additional questions posed in the response email.

1) Please add some additional information on other AR targeting agents in clinical development (e.g. Bayer ODM201, ARN509, the ISIS/AZ AR antisense drug (Yamamoto et al CCR 2015), galaterone, VT-486, and the OGX427 (targeting the AT co-chaperone hsp27)). – We have now included a table reviewing briefly the other drugs in clinical development targeting the AR axis.

2) A small change to your Competing interests section is also required; please include information for all authors here. If the other authors do not have any conflicts of interests, please add a statement to say "the other authors declare that they have no competing interests" – this has been updated to reflect this request.

Included in this online submission are:

1) Manuscript (revised)
2) Figure 1
3) Figure 2
4) Table 1

If you have questions, please call me at (732) 742-1025 or email me at tchandrasekar@ucdavis.edu.

Sincerely,

Thenappan Chandrasekar, MD